Lilly

In February 2021, Rigel entered into a global exclusive license agreement with Lilly for Rigel’s RIPK1 inhibitor program in all indications.

This collaboration includes the co-development and co-commercialization of Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.

Rigel received an upfront payment and is eligible for development, regulatory, and commercial milestone payments, as well as tiered royalty payments on any future net sales of any products emerging from the collaboration.

Click here for Press Release

Development of R552:

  • Rigel’s lead RIPK1 inhibitor, R552, has completed Phase 1 clinical trials and is expected to start Phase 2 trials in 2021 as part of the collaboration

Development of RIPK1 Inhibitors for CNS Diseases:

  • Lilly will be solely responsible for all clinical development and commercialization of brain penetrating RIPK1 inhibitors in CNS indications